OTCMKTS:WINT - Windtree Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.30 +0.30 (+7.50 %)
(As of 12/12/2018 03:50 PM ET)
Previous Close$4.00
Today's Range$4.09 - $4.31
52-Week Range$2.05 - $4.0260
Volume3,175 shs
Average Volume1,240 shs
Market Capitalization$14.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:WINT
Previous SymbolNASDAQ:WINT
CUSIP25466840
Phone215-488-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio0.06
Quick Ratio0.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.48 million
Price / Sales11.16
Cash FlowN/A
Price / Cash FlowN/A
Book Value($7.57) per share
Price / Book-0.57

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-18,440,000.00
Net Margins-562.41%
Return on EquityN/A
Return on Assets-353.42%

Miscellaneous

Employees29
Outstanding Shares3,840,000
Market Cap$14.43 million
OptionableNot Optionable

Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics Inc (OTCMKTS:WINT) announced its earnings results on Wednesday, November, 14th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.23 million for the quarter. View Windtree Therapeutics' Earnings History.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Windtree Therapeutics.

Has Windtree Therapeutics been receiving favorable news coverage?

Headlines about WINT stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Windtree Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next several days.

Who are some of Windtree Therapeutics' key competitors?

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the folowing people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 53)
  • Mr. John A. Tattory, Sr. VP, CFO & Treasurer (Age 52)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 59)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 66)
  • Ms. Mary B. Templeton, Sr. VP, Gen. Counsel & Corp. Sec. (Age 71)

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $4.30.

How big of a company is Windtree Therapeutics?

Windtree Therapeutics has a market capitalization of $14.43 million and generates $1.48 million in revenue each year. Windtree Therapeutics employs 29 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is http://www.windtreetx.com.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]


MarketBeat Community Rating for Windtree Therapeutics (OTCMKTS WINT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel